Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

BACKGROUND: There is increasing evidence that metastatic colorectal cancer (mCRC) is a genetically heterogeneous disease and that tumours arising from different sides of the colon (left versus right) have different clinical outcomes. Furthermore, previous analyses comparing the activity of different...

Full description

Bibliographic Details
Main Author: Arnold, D (author)
Other Authors: Lueza, B (author), Douillard, J-Y (author), Peeters, M (author), Lenz, H-J (author), Venook, A (author), Heinemann, V (author), Van Cutsem, E (author), Pignon, J-P (author), Tabernero, J (author), Cervantes, A (author), Ciardiello, F (author)
Format: article
Language:eng
Published: 2018
Subjects:
Anticorpos Monoclonais
Antineoplásicos Imunológicos
Bevacizumab
Cetuximab
Neoplasias Colorrectais
Genes ras
Antibodies, Monoclonal
Genes, ras
Antineoplastic Agents, Immunological
Colorectal Neoplasms
Online Access:http://hdl.handle.net/10400.26/23016
Country:Portugal
Oai:oai:comum.rcaap.pt:10400.26/23016

Internet

http://hdl.handle.net/10400.26/23016

Similar Items